Status:
UNKNOWN
Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia
Lead Sponsor:
Hormozgan University of Medical Sciences
Conditions:
Hyperbilirubinemia, Neonatal
Eligibility:
All Genders
2-28 years
Phase:
PHASE3
Brief Summary
Neonatal Jaundice occurs in 60% of term infants and 80% of premature infants. Although it is transient, it is associated with high rate of readmission of patients in the first week of infancy. Neonata...
Eligibility Criteria
Inclusion
- Between 2 and 28 days old
- Having jaundice
- Gestational age between 35-42 weeks
Exclusion
- Less than 2 days or more than 28 days old
- Gestational age out of the range of 35-42 weeks
- Infants whose parents refused to cooperate
- Patients with sepsis and other comorbid conditions
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2017
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT03266913
Start Date
August 1 2017
End Date
November 1 2017
Last Update
August 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children hospital
Bandar Abbas, Hormozgan, Iran, 763